Johnson & Johnson built its R&D rep around blockbuster development deals. Now the pharma giant's drug development arm wants the world to know that there's a comprehensive, global pipeline strategy in play that will deliver more than 10 new product applications over the next 4 years. And new drug development efforts in China and Japan are growing to rival the work it does in the U.S. and Europe.
The FDA has hit the green light for Xofigo--initially called Alpharadin or radium-223 chloride--for castration-resistant prostate cancer.
The Securities and Exchange Commission's insider trading team has Dendreon under a microscope. The agency has launched a civil investigation into stock trades by former CEO Mitchell Gold to see whether he acted on inside information about disappointing Provenge sales.
Novartis has added two more mobile apps to its constellation of digital offerings. This time, cancer patients are the target audience.
The Belgium-based company says its ConfirmMDx test reaffirmed researchers' hopes that their test could produce a more personalized--and accurate--prostate cancer diagnosis when an initial biopsy comes back negative.
Cancer patients might fail to follow their doctor's orders often. But how often do they forget their mobile phones?
Is there new hope for Dendreon's prostate cancer treatment? At least one analyst thinks so--and investors quickly hopped on the bandwagon.
Today's news that European regulators had slapped down an application from Genzyme and Isis to market their antisense drug Kynamro underscored many of the lingering concerns that have plagued this research field for years. But at Cowen, all the doubts about antisense drugs make this sector ripe for a potential surprise breakout that could significantly readjust some long-standing industry attitudes.
Chalk up an expanded use, and so an expanded market, for Zytiga, Johnson & Johnson's hot but pricey prostate cancer drug.
Bayer Healthcare is on a roll, and it has no intention of easing off the gas now. Emboldened by rising sales of Xarelto, pumped by the prospects of the macular degeneration drug Eylea and optimistic about the newly approved cancer drug Stivarga, Bayer's pharma division has outlined some ambitious plans for its $4 billion annual R&D budget.